Cytosorbents Corp. buy Quitte
Start price
11.01.16
/
50%
€4.45
Target price
11.07.16
€5.14
Performance (%)
-1.62%
End price
11.07.16
€4.37
Summary
This prediction ended on 11.07.16 with a price of €4.37. With a performance of -1.62%, the BUY prediction for Cytosorbents Corp. by Quitte closed slightly in the red. Quitte has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Cytosorbents Corp. | - | - | -76.148% | -88.717% |
iShares Core DAX® | -0.079% | -3.039% | 13.992% | 14.646% |
iShares Nasdaq 100 | 0.247% | 6.421% | 36.232% | 55.769% |
iShares Nikkei 225® | 1.918% | 0.675% | 10.784% | 5.212% |
iShares S&P 500 | 0.146% | 4.708% | 29.832% | 48.430% |
Comments by Quitte for this prediction
In the thread Cytosorbents Corp. diskutieren
auf Wachstumskurs
Growth Trajectory Continues with Record CytoSorb® Sales of Approximately $1.5M in Q4 2015 and Approximately $4.0M in 2015
MONMOUTH JUNCTION, N.J., Jan. 11, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients worldwide, issues a letter to its stockholders from Chief Executive Officer, Dr. Phillip Chan.
(Laufzeit überschritten)
Stopped prediction by Quitte for Cytosorbents Corp.
Cytosorbents Corp.
Start price
Target price
Perf. (%)
€9.12
06.11.18
06.11.18
€16.24
06.05.19
06.05.19
-24.33%
06.05.19
06.05.19
Cytosorbents Corp.
Start price
Target price
Perf. (%)
€5.14
22.12.16
22.12.16
€6.48
22.06.17
22.06.17
-23.68%
22.06.17
22.06.17